Gil Addo, SVP, Specialty Care Solutions | CVS Health and Co-founder of RubiconMD, a wholly-owned subsidiary of CVS Health. RubiconMD’s digital health platform empowers primary care clinicians with access to virtual specialist support to improve patient care. Founded in 2013, RubiconMD serves primary care clinicians across 37 states. The Huffington Post named RubiconMD one of the “Five Companies Defining the Future of Healthcare” and, in 2020, AllianceBernstein ranked RubiconMD number 12 on its list of the top 25 private companies disrupting healthcare. The company raised over $40 million in capital from top tier investment firms and in 2021 was acquired by Oak Street Health for $190 million. Prior to founding RubiconMD, Gil was a Consultant at Putnam Associates, a pharma strategy consultancy, where he designed payer and market access strategies for fortune 500 clients. He previously held strategy and business development roles at Xerox, Cubist (acquired by Merck), and two early stage healthcare ventures. Gil has appeared in Inc, Forbes, CNBC, Fortune and Entrepreneur Magazine. He’s been named one of Forbes’ “30 Under 30” in healthcare, Crains New York Business 40 Under 40 and Business Insider’s 30 under 40 in healthcare. In 2020, Crains New York named Gil to its list of the Most Notable in Health Care and in 2017 he received their Heritage Healthcare Innovator of the Year award. He holds a BS in Economics and Biomedical Engineering from Yale and an MBA from Harvard.

Payal is a Partner at .406 Ventures, where she co-leads the digital health investing practice. .406 Ventures is a Boston-based venture capital firm with ~$1B under management. The firm invests in enterprise-oriented start-ups in sectors including digital health, cybersecurity, and data & cloud. Payal’s portfolio includes AristaMD, Better Life Partners, Diana Health, Equip, Heartbeat Health, Nomad Health, Redox, Wayspring, WelbeHealth, Wellist, and Virtudent. Previously, Payal co-founded a company called SpotRocket to help students discover high-potential start-ups to work for. Payal has also worked at Eventbrite, Spectrum Equity, and J.P. Morgan. Payal received her MBA, with Distinction, from Harvard Business School and her BS in Electrical Engineering and minor in Management from MIT. She is a Boston native and she and her husband, who is a physician at Brigham and Women’s Hospital, and two kids live in Brookline.

Casey Albert is a Managing Partner at SteelSky Ventures, an early-stage venture fund investing at the intersection of technology and healthcare. She leads SteelSky’s Executive Council, which includes senior executives from Eli Lilly, Blue Shield of California, Stanford Children’s Hospital, and other leading healthcare companies. Casey has spent over 25 years investing in and scaling companies that accelerate access to healthcare. As Managing Director at Founders Factory, she oversaw new company creation and seed-stage investments in consumer health, medical devices, and life sciences, with strategic LP Johnson & Johnson. Prior to that, as head of Technology and Innovation at R4D, Casey advised senior decision-makers and innovation teams embedded in the governments of the US, UK, Canada, Australia, and Korea, on leveraging technology for healthcare innovation. Casey began her career at Deloitte, working in over 15 countries to strengthen health systems. A frequent speaker on venture investing, healthcare, and technology, Casey holds a BA from Wellesley College and an MBA and MPP from Columbia University.

Dr. Edilberto R. Alvarez is a board-certified neuroradiologist and Advanced Technology Director at VytalMed. He earned his medical degree from the FIU Herbert Wertheim College of Medicine and completed postgraduate training at the University of Miami/Jackson Memorial Hospital. Dr. Alvarez also manages the IT operations at Radiology Imaging Associates and is very passionate about harnessing new technology to advance patient care.

Working at the intersection of Patient Engagement and Digital Health, Fred is committed to using innovation to improve health outcomes. He has held leadership roles in Fortune 50 global Pharmaceutical companies, health tech start-ups, and PE funded medical communication firms. Currently, Fred is the founder and CEO of Patient Talker LLC, a start-up company focused on using AI to help patients organize and summarize their medical visits.

Gaye Bok led Mass General Brigham’s $30M AI and Digital Innovation Venture Fund (AIDIF), investing in commercial-stage digital health companies, working with the Mass General Brigham system. Prior to joining Mass General Brigham, Gaye was a venture partner at an institutional venture fund, where she was an integral part of the investment team and served as a board director on several portfolio companies. Prior to venture investing, Gaye was an experienced commercial and business development executive, focused mainly on developing products and strategic partnerships across several verticals: Chemicals, genomics, biobased energy, and biobased products. Gaye received an MBA in finance and international management from MIT’s Sloan School and an AB from Harvard and Radcliffe Colleges.

Carine Carmy is the Co-Founder and CEO at Origin, the leader in women's MSK with a specialized focus on maternity, menopause, pelvic and sexual health. She has focused her career on increasing access to products and services that improve lives, from healthcare to 3D printing. Carine's passion for women's health started in her twenties, when she struggled with painful sex for nearly a decade. Following years of misdiagnoses, ineffective treatment options, and hearing “that’s just the way it is,” Carine discovered the power of pelvic floor physical therapy to treat, not only pelvic pain, but dozens of conditions and symptoms that impact some 40 million U.S. women and individuals with vaginal anatomy, every year. Already a go-to-market leader in healthcare and technology — with leadership roles at Amino, Shapeways, MarketspaceNext, and Monitor Group — Carine felt compelled to help make pelvic health the norm for women across the country. Along with her co-founders, Carine has built a tech-forward brand and business model that brings unprecedented access, affordability, and patient satisfaction to the field of pelvic health. Origin operates virtual and in-person clinics that see over 100,000 visits per year. About 40% of Origin's patients are struggling with symptoms associated with pregnancy and the postpartum period, while the remaining 60% are struggling with conditions like endometriosis, incontinence and prolapse, as well as back and hip pain. From unique exercise videos featuring diverse bodies in a beautiful environment to establishing customized care plans for every stage of life, Origin supports both physical and emotional healing. Origin has grown to become the largest women’s PT platform nationwide since its launch in 2020, with virtual care in 50 states, 17 clinics, and 50M covered lives.

Ian is a Partner at Flare Capital, led the firm’s investment into Knownwell and was an essential part of the firm’s investments in Inbound Health and RightMove, where he serves as a board member, as well as Cayaba Care, and Oshi Health. Additionally, Ian led the firm’s Flare Scholar Ventures investments in Adni, EarlyBird Education, Narrable, and Vincere Health. Prior to joining Flare Capital, Ian served as a Senior Vice President and a founding member of CareAllies, Cigna’s family of multi-payer provider services, population health management, and home-based care businesses. In that capacity, he was responsible for developing new technology-enabled services, evolving existing solutions and service lines, and providing ongoing product management across CareAllies’ businesses. In addition, he was also responsible for developing inorganic strategies for CareAllies since its inception. Before launching CareAllies, Ian held a leadership position with Cigna’s US Strategic Operations team. Ian was a co-founder of several start-ups, including XcelDx, which ultimately partnered with Scanwell Health, a smartphone-enabled diagnostics company backed by Y-Combinator, Founders Fund, DCM, Version One, and Mayfield. He focused his efforts on product development and served as an advisor to the company. Scanwell was acquired by BD (Becton, Dickinson and Company) in 2021. He also worked for Becton, Dickinson & Company, where he led new product innovation and development. He continues to actively advise and mentor a number of innovative healthcare start-ups. He started his career at McKinsey & Company and spent five years advising healthcare clients globally. Ian serves as an advisor and board member of various organizations. He is currently a member of the Board of Directors at The New England Venture Capital Association and Harvard Business School Healthcare Alumni Association, where he also served as the 2021 Annual Conference Co-Chair. Additionally, Ian serves as an Industry Advisor at Cornell Tech’s The Precision Behavioral Health Initiative. Ian has a Bachelor of Science degree in biological engineering from Cornell University, where he graduated with honors and was a Cornell Presidential Research Scholar. He also holds an MBA from Harvard Business School.

Heather Deixler counsels public and private companies on complex transactional and regulatory matters at the intersection of healthcare, life sciences, and technology. Heather draws on extensive digital health industry experience to advise healthcare providers and healthcare systems, as well as digital health, e-commerce, medical device, therapeutics, genetics, and bioscience companies, on cutting-edge matters and initiatives involving: • Innovative healthcare delivery systems, including value-based enterprises, clinically integrated networks, independent physician associations, Medicare accountable care organizations, and other value-based payment programs • AI and machine learning solutions • Data rights • Data use and protection • Genomic privacy • General data privacy and security matters, including data privacy and security policies and procedures as well as online privacy policies and terms of service • Information blocking and interoperability • Real-world data and evidence generation • Data breach response A practical problem-solver, Heather is a Certified Information Privacy Professional (CIPP/US and CIPP/E) and guides clients on all regulatory and legal aspects of digital health, including: • Stark Law, the Federal Anti-Kickback Statute, and state law equivalents • Health Insurance Portability and Accountability Act (HIPAA) • California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA) • Children’s Online Privacy Protection Act (COPPA) • Federal Trade Commission Act • CAN-SPAM • Telemarketing laws • Self-regulatory and online behavioral advertising guidelines A recognized leader at the firm, Heather serves on the Digital Health Task Force and the Data Privacy Committee. Heather previously served as an adjunct professor in the University of Washington School of Law’s Health Law LLM program. Before attending law school, she worked as a research technician in a neurophysiology laboratory in Dijon, France, and as a clinical research assistant at the Beth Israel Deaconess Medical Center in Boston.

Parth is a Partner at Flare Capital Partners. Parth has a background in healthcare policy, operating, innovation and investing. At Flare Capital he is a lead/co-lead investor and Board Member at SmarterDx, Board Observer at Layer Health, Board Observer at Photon Health, Board Observer at Positive Development, Board Observer at BeMe Health and investor in Flare Scholar Ventures investments Birch AI (acquired by Sagility), Jaide Health, Rosarium Health and Helm Health. Parth also supports or has co-led Flare Capital’s investments into Aetion, HealthVerity and Suki AI. He previously supported Bright Health (IPO) and HealthReveal (acquired by Accolade). Additionally, Parth is a member of Boston University School of Public Health’s Advisory Committee and Alumni Leadership Council. Prior to joining Flare Capital, Parth was an investor at NewYork-Presbyterian Hospital (NYP) Ventures, where he focused on applications of artificial intelligence to healthcare operations, leading investments into Saykara (acquired by Nuance), Syllable AI and Workfusion. In addition to venture investing, he also worked with the hospital’s executive leadership team to commercialize internal innovation and structure strategic partnerships to enhance the hospital’s patient and clinician care experience. Prior to joining NYP Ventures, Parth was a health care strategy consultant at Deloitte Consulting, responsible for developing corporate growth strategies, advising M&A transactions and supporting operational transformations for leading providers, payers and technology companies. Parth began his career as health policy analyst for the Massachusetts House of Representatives, where he primarily worked with the Patrick administration to manage reform of the pharmaceutical compounding industry, authoring legislation signed into law by Governor Deval Patrick and used by the FDA to model national regulations. Parth earned his BS in Biology from Boston College, MPH in Health Policy and Management from Boston University School of Public Health and Masters in Medicine from Boston University School of Medicine.

Caitlin Donovan is a highly recognized builder and operator in the healthcare space who shares our commitment to make health assurance a reality – where healthcare is more accessible, proactive and affordable for all. Caitlin was most recently the Global Head of Uber Health, Uber’s business unit focused on creating a first-of-its-kind supplemental benefit platform offering non-emergency transportation, prescription delivery, grocery, and over the counter item benefits to Medicare Advantage, Managed Medicaid, and Commercial populations. During her 3 year tenure there, she substantially scaled the business, reimagining how technology intersects with healthcare. Prior to Uber Health, she served as Chief Operating Officer and VP Operations in a variety of businesses focused on medical transportation, home health, multi-clinic providers and post-acute care. Early in her career, she worked as an investor at Bain Capital and at Summit Partners where she built a strong understanding of finance. She earned her bachelor's degree in Economics from Harvard University and lives in Dover, Massachusetts with her husband and two boys.

Adaeze Enekwechi, PhD, MPP is the CEO of Cayaba Care maternal health company focused on improving outcomes for moderate and high risk pregnant women covered by Medicaid and commercial insurance. Cayaba provides a full-suite, wrap-around services model in the home, in person and virtually to supplement existing OB care with health related social needs during pregnancy through postpartum to ensure that women at risk experience excellent maternal outcomes. A value-based care company, Cayaba Care is focused on bridging the gaps in maternal outcomes for women in urban, rural, and often underserved communities. Dr. Enekwechi is also an Operating Partner at WCAS, an investment firm where she focuses on growth-oriented healthcare companies. She sharpens the firm's understanding of the policy and regulatory environment which can have a significant impact on healthcare companies particularly companies serving Medicare and Medicaid populations. Dr. Enekwechi is trained in health economics and outcomes research, and led IMPAQ, LLC, a company that provided research, technical assistance, and advanced analytics services for federal clients which she led through its M&A process and acquisition in 2020. She also spent many years in federal policy roles at the Congressional Budget Office (CBO), the Medicare Payment Advisory Commission, and she was the Head of Health Programs at the White House Office of Management and Budget under President Obama. There she led policy, management and regulatory oversight for all US health care agencies and programs including CMS, FDA, NIH, CDC and HRSA. Dr. Enekwechi serves on the board of directors at MedStar Health, Liberty Dental Plan, and the Alliance for Health Policy. She is based in the Washington, DC area.

Brenton joined Lightspeed as a Partner in 2025 to lead Healthtech investing at the firm, with a particular focus on AI’s role in reshaping the healthcare landscape. Previously, he worked closely with Kevin Ryan, the”Godfather of NYC tech,” at AlleyCorp where he started its Healthcare team and led it to become the most active Healthtech investor in the country (per HSBC Annual Venture Healthcare Report 2024). At AlleyCorp, Brenton served as first investor and board member in value-based care startups like Thyme Care and Pearl Health and healthcare AI startups like Clarium Health. Prior to AlleyCorp, Brenton was an early employee at Flatiron Health and helped build its value-based care business from the ground up, served on its leadership team through acquisition by Roche for ~$2B, and was instrumental in the launch of OneOncology which went on to be acquired by AmerisourceBergen and TPG for ~$2B. He also worked previously at J.P. Morgan in its Healthcare Investment Banking Division, as well as at Blue Cross & Blue Shield. Brenton started his career as a physician. Board-certified in Internal Medicine, he previously practiced at Memorial Sloan Kettering Cancer Center and completed residency at Harvard’s Brigham and Women’s Hospital. He graduated summa cum laude from the University of Pennsylvania, earning an MD from the University of Pennsylvania School of Medicine and an MBA in Healthcare Management from the Wharton School. While practicing medicine, Brenton was struck by how antiquated the technology stack is for healthcare delivery — from pagers to faxes to electronic health records. At the first startup he joined, Flatiron Health, he saw the important role venture capital played in its outsized growth. From his time practicing and operating in startups, he was convinced that venture capital was the vehicle to drive the innovation healthcare technology so direly needs, and ultimately create a new standard of care delivery for patients. A long-time champion of the “Doctorpreneur” community, Brenton immediately felt at home with Lightspeed’s like-minded doctors on the Healthcare investment team and physician entrepreneurs within the portfolio such as with Abridge and Aledade. Based in New York City, Brenton is an avid supporter of the New York healthcare ecosystem and serves on the boards of Fund for Public Health NYC, Digital Health New York, and was named Crain’s New York 40 under 40

Rushika Fernandopulle is a practicing physician and Chief Innovation Officer of One Medical, a leading Advanced Primary Care company based in San Francisco, CA. Before this, he was co-founder and CEO of Iora Health, was the first Executive Director of the Harvard Interfaculty Program for Health Systems Improvement, and Managing Director of the Clinical Initiatives Center at the Advisory Board Company. He is a member of the Albert Schweitzer, Ashoka, Aspen, and Salzburg Global Fellowships, and is co-author or editor of several publications. He serves on the staff at the Massachusetts General Hospital, on the faculty of Harvard Medical School. He earned his A.B., M.D., and M.P.P. from Harvard University, and completed his clinical training at the University of Pennsylvania and the Massachusetts General Hospital.

Katerina is Investment Director at Philips Ventures, a corporate venture arm of Philips. She is focused on digital health and health tech investments aligned with Philips’ mission to improve health and well-being through meaningful innovation. Katerina's passion lies in scaling tech-innovative businesses, driving impactful M&A, and supporting visionary entrepreneurs, often in dynamic and challenging markets. She works closely with early- and growth-stage portfolio companies, guiding them through commercialization and scaling operations. She currently serves on the boards of Orbita.AI, MOVN Health, Babyscripts, PreciseDx, and Noninvasix, and have supported successful exits, most recently Carevive/Health Catalyst. Katerina has earned her MBA from MIT Sloan. She is a mentor and judge at MassChallenge, an organizing committee member for the MIT Sloan CFO Summit, an active participant in AI Innovators Community (AIC), advisor, and a frequent speaker at conferences including DHIS, LSX, LSI.

With over two decades of experience in finance, M&A, and venture capital, Katarina brings a unique blend of adaptability, strategic growth, and smart investing to the table. Her passion lies in scaling tech-innovative businesses, driving impactful M&A, and supporting visionary entrepreneurs - often in dynamic and challenging markets.

Keith J. Figlioli joined LRVHealth in 2016, as a General Partner after nearly two decades of experience building and growing healthcare IT and services companies. Before joining LRVHealth, Keith was Senior Vice President of Healthcare Informatics at Premier, Inc. (NASDAQ: PINC) where he led the company’s enterprise healthcare technology business unit and helped the company raise $820M in its IPO. Prior to Premier, Keith was Senior Vice President of Enterprise Solutions at Eclipsys (acquired by Allscripts NASDAQ: MDRX). He is a board member of IntelyCare, Upfront Healthcare, Season Health, Censinet, and Reimagine Care, and a board observer for Diana Health, Genome Medical, and Xealth. He previously served on the Board of Trustees at Wheaton College, the Strategy Committee of Baystate Health, the Health IT Standards Committee for the Office of the National Coordinator (ONC), and the board of directors for Global Healthcare Exchange (GHX), Activate Networks, Good Sports, and MassBike. Keith earned his B.A. from Wheaton College, M.B.A. from Boston University, and M.P.H. from Harvard T.H. Chan School of Public Health.

Robert is currently a Managing Partner at 7wire Ventures, where he focuses on investments in digital healthcare and technology-enabled services that empower consumers to be better stewards of their health in today’s changing healthcare ecosystem. Robert currently sits on the boards of Cylinder Health, GroundGame.Health, Homethrive, and RecoveryOne. Robert has over 30 years of experience investing in, advising, and operating early-stage healthcare and technology companies and has co-managed five venture funds with $600M+ AUM. Before joining 7wire Ventures, Robert served as Managing Director of Stratus Ventures and KB Partners where he led investments in early-stage healthcare and technology companies. Previously, Robert held key executive roles for three high-growth companies where he led operations, business development, and finance in the ecommerce and software industries. Robert received a Master of Business Administration degree from the Kellogg Graduate School of Management and a Bachelor of Arts degree from the University of Pennsylvania.

Anna Haghgooie is a Managing Director at Valtruis, a Welsh, Carson, Anderson & Stow (WCAS) company and an Operating Partner at WCAS. Valtruis, is a unique platform that invests in and partners with disruptive leaders whose mission is to align and transform healthcare through value-based care. Valtruis is investing +$600M into companies and building portfolio support capabilities to help our companies take on and manage risk at scale. Previously, Anna was a Managing Director of the Blue Venture Fund and Sandbox Industries. The Blue Venture Fund is a unique collaboration between BCBS companies, BCBSA, and Sandbox, where she managed over $900M in capital across four funds. Anna currently serves on the boards of Wayspring, InStride Health, Oncology Care Partners, TailorCare, and Tuesday Health. She previously served on the boards of Contessa, PWN Health, ExactCare, naviHealth, Change Healthcare, Quilted Health, Somatus, ZeOmega, and SonarMD. Anna earned a bachelor’s degree from the University of Michigan and a MBA with honors from the University of Chicago Booth School of Business. Anna is a Fellow in the Health Innovators Fellowship at the Aspen Institute and lives in Chicago, IL with her husband and two children.

Joe Hammer has over two decades of experience in the financial services and healthcare industries. He leads the Life Science and Healthcare practice for CIBC Innovation Banking. Previously, he was the Managing Director of Silicon Valley Bank’s Life Science and Healthcare Corporate Banking practice, working with middle-market private and public companies across the U.S. Prior to SVB, Joe was the Chief Development Officer at a life sciences subsidiary specializing in business process outsourcing for orphan drug, biopharma, and medical device manufacturers.

Julian Harris, M.D., is an Operating Partner on the Healthcare Services team at Deerfield and joined the Firm in 2019. Dr. Harris works with a variety of health care services and technology companies that are both current and potential investment partners. He is also Chairman and Chief Executive Officer of ConcertoCare, a leading tech-enabled, value-based care provider of at-home comprehensive care for seniors with unmet health, behavioral and social needs. Before Deerfield, Dr. Harris was the founding President of CareAllies, Cigna’s family of multi-payer provider services and home-based care businesses. Previously, he led US Strategic Operations for Cigna and managed a $500M internal investment portfolio focused on technology and innovation. Dr. Harris was also an Adviser to Google Ventures (GV) focused on health care services. Before GV, he led the health care team in the White House Office of Management and Budget (OMB). As the federal government’s chief health care finance official, he oversaw a $1 trillion budget and provided management and policy oversight for a range of programs, including Medicare, Medicaid, FDA, NIH and CDC. He also served as the chief executive of the $11 billion Massachusetts Medicaid program. Dr. Harris trained in internal medicine and primary care at Harvard Medical School’s Brigham & Women’s Hospital and practiced as a hospitalist at Cambridge Health Alliance and as a clinical consultant for the digital second opinion company, BestDoctors (acquired by Teladoc). He graduated summa cum laude with a B.A. in Health Policy & Medical Ethics from Duke University and holds an M.Sc. from Oxford University, where he studied as a Rhodes Scholar. He is also a graduate of the Wharton School of Business and the University of Pennsylvania’s School of Medicine, where he currently serves as an Adjunct Professor. Dr. Harris is a trustee of the New York Academy of Medicine and a member of the advisory board for the Leonard Davis Institute for Health Economics at Penn.

Marc Harrison, M.D. is a global healthcare leader, recognized for healthcare transformation and health equity advocacy. He is a pediatric critical care physician, and is the former president and CEO of Intermountain Healthcare. Dr. Harrison has joined the venture capital firm Gener Catalyst to launch and lead Health Assurance Transformation Company (HATCo), a new business with the mission to deliver health and wellness collaboratively, compassionately, and courageously – for all people. As president and CEO of Intermountain, Dr. Harrison led the organization to reimagine healthcare operations and champion innovation and collaboration to ensure that its 60,000 caregivers had access to the technology and tools to best reach, serve, and empower patients. In his first five years leading the organization, he executed a disciplined growth strategy significant investments in telehealth and rural health to expand Intermountain’s service ar from primarily Utah communities to serving patients throughout the Mountain West. Under his leadership, Intermountain embraced unconventional, public-private partnerships to confront some of the most pressing systemic challenges facing communities and industry to proactively keep people well and make communities healthier. Those initiatives were a catalyst for the national movement toward value-based care, advancing clinical education, and establishing a new Digital Hippocratic Oath (developed by Graphite, a company co-founded by Intermountain) to improve hospital data interoperability and secure patient privacy rights. During his tenure, Intermountain partnered with more than 1,000 hospitals nationwide to launch Civica Rx, a nonprofit generic drug manufacturer and distributor, to make gener medications—including insulin, which they plan to offer in 2024—more accessible and afforda Intermountain was a founding member of the Utah Alliance for the Determinants of Health, a collaboration of community partners proactively addressing forces that affect people’s ability stay healthy. Additionally, Intermountain partnered with an international genomics leader and more than 100,000 volunteers to advance medical breakthroughs that will help prevent and treat genetic diseases for people around the globe. Before leading Intermountain, Dr. Harrison served as CEO of Cleveland Clinic Abu Dhabi, chief of international business development at Cleveland Clinic, and chief medical operations officer Cleveland Clinic. Fortune recognized him as one of the Top 50 World’s Greatest Leaders in 2019, and Modern Healthcare has consistently recognized him among the Most Influential People Healthcare. Dr. Harrison is the author of Possibility Unleashed: Pathbreaking Lessons for Making Change Happen in Your Organization and Beyond, a guide for leaders to face their fears, transcend discord and polarization, and drive positive systemic and societal change. Dr. Harrison received his undergraduate degree from Haverford College and his medical degree from Dartmouth Medical School. He completed a pediatric residency and pediatric critical care fellowship at Intermountain’s Primary Children’s Hospital, and earned a Master of Medical Management at Carnegie Mellon University. He is an all-American triathlete, and represented the U.S. at the 2014 World Championships. He is also a two-time cancer survivor and nine-time Ironman participant. He is a loving husband and proud father of three adult children.

Julia Hu is the co-founder and CEO of Lark, an A.I. Cardiometabolic and GLP1 Cost Containment Platform providing scalable, compassionate chronic disease management. Inspired by her own health challenges, she is happy that Lark has treated 2.5 million patients for their health plan, employer, and PBM partners. Julia was named Inc's 30 Under 30 and inducted into UCSF Health's Hall of Fame and named an EY Entrepreneurial Winning Woman. Previously, she led a global startup incubator and was an Entrepreneur-in-Residence at Stanford’s StartX. Julia has served on several nonprofits- Silicon Valley Leadership Group, Council for Diabetes Prevention, and was faculty at Singularity U.

I am a healthcare executive with over 20 years of experience. I am an expert in government healthcare programs for Medicaid and duals, a technologist with experience operating business and tech teams and end to end capital management and deep experience in healthcare innovation including value based care, complex care delivery models and consumerism. Proven ability create business opportunities, drive pragmatic innovation at scale in a complex organization and strategically position for current and future market dynamics that impact revenue & growth.

Kevin Jackson is the Chief Operating Officer at AlgometRx, Inc, a medical device company developing a novel technology for objective pain assessment. Kevin and AlgometRx are focused on developing this technology to enable better treatment decisions and improve precision in the management of pain. At AlgometRx, Kevin leads product development, clinical partnerships, and operational scale-up. The company has secured competitive funding from agencies including the NIH and ARPA-H to support the advancement of its core technology. Kevin brings a multidisciplinary approach to addressing one of healthcare’s most persistent challenges and is committed to advancing patient-centered innovation at the intersection of technology and medicine.

Zeena Johar joined Frist Cressey Ventures as an Entrepreneur in Residence to further her passion to continue serving vulnerable populations on Medicaid by leveraging innovative technology enabled solutions. As a healthcare entrepreneur Zeena has dedicated her career to building companies for the underprivileged, underserved and the vulnerable. Previously, Zeena was with Rubicon Founders where she Co-Founded Imagine Pediatrics (IP) along with Oak HC/FT and Optum Ventures. IP as a pediatric value-based care company, works to support the sickest-of-sick kids, by providing them 24*7 virtual and in-person support. As the Chief Growth Officer, Zeena led Imagine’s strategic partnerships with Centene and United Healthcare across TX and FL. Before joining Rubicon, Zeena led operations at Advantia Health. Advantia is now one of the largest Women's Health roll-ups with 50 Offices (across 4 States plus district) and >200 Obstetrics & Gynecology providers. Before joining Advantia Health, Zeena worked in health policy with Dr. Mark McClellan (previous FDA Commissioner & CMS Administrator). In 2007, Zeena Co-Founded SughaVazhvu Healthcare (SVHC) along with Dr. Nachiket Mor in India. SVHC, as first-of-its-kind technology enabled primary care platform, set-up clinics in rural India to support disease management for chronic conditions such as diabetes and hypertension. As CEO in 8 years, Zeena grew SVHC to 10 primary-care clinics, serving >100K patients visits. SVHC was showcased as a Case Study by The Brookings Institute. SVHC was also awarded the NASSCOM Social Innovation Honor 2014 for its innovation in healthcare delivery and use of mobile technologies. Zeena received her PhD in Molecular Diagnostics from ETH, Zurich, Switzerland. Zeena is a Harvard Business School alum (Program for Leadership Development) and was elected as an Ashoka Fellow in 2013, Aspen Global Leadership Network (AGLN) Fellow 2014, as one of Asia’s 100 Pioneers by Purpose Economy in 2014 and Yale World Fellow 2015.

Chris Johnson is the founder and CEO of Bluebird Kids Health, a pediatric primary care organization serving over 20,000 patients. Through value-based care partnerships with payers, Bluebird Kids Health delivers comprehensive care by integrating physical, mental, and social health services. Its innovative clinical model is supported by a population health technology platform, which ensures proactive access to care tailored to the needs of each child. Before founding Bluebird Kids Health, Chris served as the Chief Executive Officer of Landmark Health, an organization specializing in in-home primary care for seniors with serious illnesses in value-based partnerships with Medicare Advantage plans. Under his leadership, Landmark expanded its operations from 10 to 38 states and grew its patient base from approximately 150,000 to 700,000. Chris also guided the organization through its integration with Optum, where Landmark became a cornerstone of Optum’s Home and Community portfolio. Chris resides in Newton, Massachusetts with his wife, Devon, and their three young children. In his free time, he enjoys exploring the outdoors with his family.

Dr. Kang is a progressive Healthcare and Physician executive with diverse and extensive experience in multiple health care settings including health insurance, a globally capitated “medical home," the federal government and retail health care. Skilled in policy, program and product development, operations, turnaround, business development and running successful P&L’s. Uniquely positioned to run a full risk, globally capitated physician group or a health plan strategically aligned with healthcare providers. Reputation for strategic acumen and translating strategic direction into new business models and growth.

Joscelyn is VP of Operations at Lura Health, a biosensor company developing the first continuous health wearable that uses saliva instead of blood. She has over 10 years of leadership experience driving product strategy, operations and design in both high growth startups and scrappy founding teams. Joscelyn graduated with highest honors from University of California, Berkeley and earned her Masters in Healthcare Administration from Mailman School of Public Health at Columbia University.

Vic is a Partner at Flare Capital Partners. Vic led the firm’s investments in Elektra Health, Greater Good Health, Lynx, and Ounce of Care. In addition, in the past he held Board observer roles with Aspen RxHealth, Axuall, Circulation (acquired by LogistiCare), Cohere Health, Oui Therapeutics, Tausight, Visana Health, Visitpay (acquired by R1), and Vita Health. He also has led the firm’s Flare Scholars Ventures investments Marigold Health, Piction Health and Ounce of Care.

Andrea Linna of Wilson Sonsini will provide a high-level overview of key legal and compliance issues facing digital health companies today, including the latest developments in corporate practice of medicine (CPOM) enforcement, the use of AI in clinical decision-making, online prescribing, and shifting standards for healthcare data privacy. Attendees will gain practical insights into navigating regulatory risks, building compliant business models, and anticipating legal scrutiny in a time of rapid innovation.

Nawa Lodin is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where she is member of the firm’s digital health industry group and its healthcare practice. Nawa represents clients in a full range of corporate transactions and compliance matters and provides guidance on a wide variety of state and federal laws and regulations including: the Health Insurance Portability and Accountability Act (HIPAA), Medicare and Medicaid fraud and abuse laws, the Stark Law, the Anti-kickback statute, corporate practice of medicine, use of artificial intelligence and machine learning, fee-splitting, and scope of licensure compliance. Nawa has extensive experience on healthcare transactions, including mergers and acquisitions, venture and growth equity financings, and capital markets transactions, and has represented clients in acquisitions and financings involving a wide variety of healthcare providers, digital health, and life sciences companies. Nawa handles a range of healthcare matters including advising start-ups, drafting and negotiating clinical trial agreements, medical staff issues, telemedicine matters and providing healthcare compliance plans and training. Prior to joining the firm, Nawa was an associate at Simpson Thacher & Bartlett. Before that, she was an associate at Goodwin Procter. Nawa serves on the Board of Directors for Women for Afghan Women, the largest non-governmental Afghan women’s right organization in the world. She is fluent in Dari.

Dr. Aditi Mallick most recently served in senior leadership roles at the Center for Medicare and Medicaid Services (CMS), including Director of Clinical Strategy, Director of the Office of Minority Health (the health equity office within CMS), and Chief Medical Officer for Medicaid and CHIP. Her work focused on clinical strategy and cross-agency work on health equity, social determinants of health, value-based care, maternal health, behavioral health, and quality measurement among other areas. Prior to CMS, Dr. Mallick ran statewide COVID-19 response efforts for the North Carolina Department of Health and Human Services and was an engagement manager in the healthcare practice at McKinsey & Co. Dr. Mallick brings her experience caring for patients to her work. She earned her A.B. with honors from Harvard College, her M.D. from Stanford University School of Medicine, and completed internal medicine residency at Massachusetts General Hospital and Harvard Medical School before serving on the clinical faculty at Johns Hopkins and George Washington University Hospitals.

Raghav Mani is the Director of Digital Health, focused on building agentic AI products and platforms for providers, payors and pharma. Prior to NVIDIA, Raghav worked at Epic, where he led different product and engineering teams including their Deep Learning team and their patient engagement platform called MyChart. He holds a bachelor’s degree from Indian Institute of Technology in Madras and a master's degree from Texas A&M University.

Martyn Mason brings over 15 years of experience at the intersection of software development, enterprise technology, and AI innovation. As CEO of Nymbl, he leads with a vision to transform how businesses leverage custom AI solutions to modernize legacy systems, streamline operations, and accelerate growth. With a strong background in tech sales and cross-functional leadership, Martyn bridges the gap between executive stakeholders and technical teams to deliver scalable, intelligent solutions that drive real business outcomes. Under his leadership, Nymbl empowers enterprises to adopt AI with confidence—through strategic system-level thinking, rapid prototyping, and a culture centered on learning, building, and growing.

Danny Metzger-Traber is Vice President of Strategic Business Operations for Mass General Brigham Healthcare at Home, overseeing strategic direction for home-based service lines, including one of the nation’s largest Home Hospitals and New England’s largest Home Care agency. He previously held senior strategy roles at the Massachusetts Medicaid Agency and Optum. As a healthcare consultant at Oliver Wyman, Danny drove enterprise strategy development across payers, providers and life sciences companies. Danny specializes in expanding value-based care, integrating clinical and technology assets, and scaling home-based care solutions.

Stefanie is an obstetric nurse with 25+ years of experience, dedicated to improving maternal care and reducing disparities, particularly in postpartum hemorrhage and maternal morbidity. Throughout her career, she has worked primarily with underserved and minority populations in high-volume urban hospitals, witnessing firsthand the impact of inequitable care. Holding a master’s in Innovations and Intra/Entrepreneurship in Advanced Practice Nursing, Stefanie brings together clinical expertise, entrepreneurial experience, and project management skills to develop predictive tools for postpartum hemorrhage. She co-led a proof-of-concept study on HR data to support this work and currently mentors over 50 former nursing students, teaches clinical obstetrics at the University of Pennsylvania, and conducts research on the effects of the ARRIVE trial implementation.

Brenna O'Riordan is a Senior Program Officer focused on Health Commercialization at VentureWell. Currently, Brenna manages heath commercialization programs with the Investor Catalyst Hub, a regional hub based out of Cambridge, MA, for Advanced Research Project Agency for Healthcare (ARPA-H). Prior to joining VentureWell, Brenna worked in the digital health space at Boston Scientific, Walgreens Health, Verily Life Sciences and Google.

I have spent over 20 years across multiple sectors of healthcare, ranging from clinical to commercial, health policy to technology. I am attracted to roles that drive growth and change, and to missions that apply innovation to improve the state of our healthcare industry. I have returned businesses to growth by transforming portfolios, aligning across organizations, and building strong teams. I execute strategically. That means I design the strategy if there isn’t one, refine it if it’s not quite right, socialize it so everyone is clear on the north star, identify competencies and metrics for organizational rigor, and operationalize it so we execute successfully. I am accountable for results, and proactively manage the P&L with an eye on top and bottom line growth. I build a culture that empowers others to be accountable, while having fun. I have demonstrated success navigating complex organizations, and have made a career out of driving change from within the extra-complex ecosystem that is healthcare. I have found that doing so requires a high level of optimistic fortitude. Consider me a happy warrior for change.

Mike Pykosz is the co-founder and former Chairman and Chief Executive Officer of Oak Street Health, a leading network of primary care centers that delivers value-based care to adults on Medicare. Under Mike’s leadership, Oak Street Health’s team of more than 6,000 Oakies is rebuilding healthcare as it should be. His strategic guidance enabled the organization’s growth to more than 250 centers across 27 states since its founding in 2012. In May of 2023, Oak Street was acquired by CVS for $10.6 B. Following the acquisition, Mike served as EVP and President of Health Care Delivery at CVS until his departure in Dec, 2024. In this role, he oversaw strategy and operations and across CVS Health’s health care delivery assets. Mike was recognized as one of Modern Healthcare’s “100 Most Influential People in Healthcare” in 2023 for the fourth consecutive year, and one of Business Insider’s “100 People Transforming Business” in 2020.Prior to founding Oak Street Health, Mike served as a core member of the Payers and Providers practice at The Boston Consulting Group, where he led projects focused on caring for the Medicare population and their unique healthcare needs. Mike has a BS in Biochemistry from the University of Notre Dame and holds a JD from Harvard Law School.

As a Partner and Executive Director at CVS Health Ventures, I lead the early and mid-stage investment program in digital health start-ups. I aim to make an impact through bridging the gap between CVS Health and the start-up ecosystem, and driving meaningful partnerships that bring new digital experiences to users in healthcare. I have led investments and partnership execution in areas spanning virtual specialty care, women's health, behavioral health, digital therapeutics, and more. I am passionate about digital innovation in healthcare and its potential to improve lives and outcomes.

Dr. Caleb Rivera is the President of VytalMed and has been in private practice as a Radiologist in Ocala, Florida for the past 25 years with Radiology Imaging Associates. The practice began with only 15 physicians in 2000 and has grown to more than 120 Radiologists with broad reach from Virginia to the USVI. The practice has a diversified portfolio beyond the initial practice that includes imaging center ownership and management, real estate holdings, and an early stage Telerad company. He has served as the president of these companies since 2016.

Gregory Ryslik is a statistician, data scientist and artificial intelligence researcher with experience building and leading data initiatives in companies across the biotech, autotech, healthtech and fintech domains. Greg leads Artificial Intelligence, Engineering & Data Efforts at Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Prior to Compass, Greg Ryslik was the Chief Data Officer at Celsius Therapeutics in Cambridge, MA, a biotechnology company focused on single cell RNA sequencing. Prior to that, he was Vice President of Data Science at Mindstrong Health, a healthcare company transforming mental health treatment through measurement science and artificial intelligence. Greg has also spent time in the automotive sector, first at Tesla Motors, leading the Service Data Science group in Palo Alto, CA and then as the Head and Senior Director of Data Science at Faraday Future in Los Angeles, CA. Earlier in his career, he performed machine learning research and nonclinical biostatistics research at Genentech and was an actuary in New York City at PricewaterhouseCoopers. Greg lectures on statistics for artificial intelligence and machine learning at Stanford Continuing Studies and is an Assistant Professor of Practice at The Ohio State University. He is also a fellow of the Casualty Actuarial Society, as well as a member of the American Academy of Actuaries. His research has been published in journals ranging from Nature to BMC Bioinformatics and has led to several software packages on mutational clustering. Greg holds a PhD from Yale University in biostatistics, a master’s degree in statistics from Columbia University and an undergraduate degree in mathematics, computer science and finance from Rutgers University.

Dr. Said is the Founder and CEO of Outcomes4Me, a health technology company focused on empowering cancer patients with personalized, evidence-based navigation and improving outcomes through better access to innovation. Prior to founding Outcomes4Me, she was Senior Vice President of Global Market Access & Policy at Novartis Pharmaceuticals and Vice President of Strategy & External Innovation at Sanofi. Dr. Said is a strong advocate for life sciences innovation and serves on the Board of Directors of Transgene, Pieris Pharmaceuticals, and Home Biosciences. She was a founding member of the Boston Consulting Group Strategy Institute. Dr. Said trained at the Massachusetts Institute of Technology, earning dual degrees in Biology and Electrical Engineering and Computer Science with a minor in Economics. She also holds a Master of Science in Toxicology, a Master of Engineering in Electrical Engineering, and Computer Science, and a Doctor of Science in Electrical Engineering, Computer Science, and Systems Biology, all from MIT.

Josh is the global chair of Cooley’s digital health group and serves on the firm’s Life Sciences Advisory Board. He represents life sciences, healthcare and technology clients through the full company life cycle, from seed stage through private financings, M&A and initial public offerings. He also regularly advises clients on general corporate issues, securities matters and implications of proposed business transactions.

Our mission at Phare Health is to make reimbursement fair and transparent so that healthcare organizations can spend more time focusing on patients and less time on negotiating price tags. We've assembled some of the best AI talent in the world to tackle the hardest challenges in revenue cycle, beginning with complex medical coding. Before Phare, I helped build data-driven electronic health record products at Google and DeepMind, trained in informatics at Stanford, and worked as a doctor in Australia.

Michelle Snyder brings over 25 years’ healthcare industry experience in marketing, business development, strategic planning, public policy, and general management. Prior to joining McKesson Ventures, she was Chief Marketing Officer at Welltok as well as an early executive at Epocrates, where she worked for over a decade to build the company into one of the most recognized brands among clinicians. Her MV investments include CancerIQ, Galileo, Inbound Health, Reimagine Care, and RxVantage. Michelle has also served as an Executive-in-Residence at InterWest Partners, investing in digital health companies and advising portfolio companies. In addition, she has held consulting and policy positions at The Wilkerson Group, the Lewin Group and the Georgetown Center for Health Policy Studies. Michelle earned her M.B.A. at the Kellogg School of Management at Northwestern University and her B.A. from Carleton College. Though she’s been in the Bay Area for over 20 years, she still dons green and gold and wears her Cheesehead proudly on Sundays.

From clinician to healthcare policy expert, my journey began as a Doctor of Physical Therapy with a passion for solving problems beyond individual patient care. While working in home health, I developed a program bringing total joint patients to home care instead of inpatient rehab, generating significant revenue and better outcomes. This experience revealed my ability to create systemic change. A defining moment came when I encountered a terminally ill patient with pancreatic cancer receiving daily therapy while in excruciating pain because the system incentivized billable units over appropriate hospice care. She died just 12 hours after I finally secured hospice services for her. That day, I committed to addressing the broken incentives in our healthcare system.

Hamid Tabatabaie serves as Chief Executive Officer and President at CodaMetrix. He has been at the forefront of innovation in medical informatics for over 30 years. His vision, experience, and insight have helped launch and grow a number of successful healthtech startups. Prior to joining the company, he was the Founder and served as Chief Executive Officer at lifeIMAGE, the most utilized cloud-based service for the exchange of diagnostic imaging information. Prior to that, he was the first Chief Executive Officer at AMICAS and took the company from concept to a leader in image management within 4 years. He started his entrepreneurial career in 1993 as the founder and Chief Executive Officer at Systems Concepts (SCA), a fast-growing HIT implementation consultancy firm. Currently, he serves as Board Member and Advisor to several technology start-ups and not-for-profits.

Adam Tweedy leads the investor coverage practice for SVB’s life science and healthcare business. He and his team provide tailored services, industry insights and strategic guidance to top investors in the innovation economy. Before taking on his current role, Adam lead a team focused upon delivering solutions for the liquidity needs of the bank’s corporate clients. Prior to this, Adam helped to build and lead SVB’s Global Fund Banking business, delivering solutions to the bank’s venture capital and private equity firm clients. Adam was instrumental in helping build this business unit from a small niche provider into a global practice leading SVB to become the premier partner to investors in the innovation economy. When Adam joined SVB in 2001, he brought significant experience in startup and international business to the bank as a co-founder and chief financial officer for a startup and as a management consultant. Adam began his banking career as a relationship manager at Fleet National Bank in its acquisition finance division. Adam holds a master’s degree in business administration from the F.W. Olin Graduate School of Business at Babson College, has held series 7 and 63 securities licenses, completed the Tuck Leadership and Strategic Impact Executive Education program at Dartmouth, and holds a bachelor’s degree from Washington & Jefferson College.

Sharif is a healthcare executive, physician and clinician educator. He is the co-founder and CEO of UpDoc, a healthcare AI company pioneering a model of clinician-supervised AI care delivery known as Remote Patient Intervention (RPI). Sharif is also a primary care physician on faculty at Stanford and an investor at Polaris Partners, where he focuses on digital health and life sciences investments.

Megann Vaughn Watters is an experienced corporate development executive and investor with over a dozen years of novel technology identification, partnership development, deal execution, alliance management, financial and strategic return, and venture-backed board experience within the healthcare industry. As the Vice President of New Ventures & Strategic Alliances and Managing Partner of Labcorp Venture Fund, Megann manages the venture fund and leads the Corporate Development team tasked to identify, assess, and bring innovative science and technology to Labcorp through partnerships, such as equity investments, licensing, commercial collaborations, including data use agreements and sponsored testing programs with pharma. As one of the founding members of the Labcorp Venture Fund, Megann has managed more than $300M in total equity investments in over 80 early-stage private companies with novel science and technology making healthcare more convenient, accessible, data-driven and personalized. Megann previously held positions at the United States Patent and Trademark Office as a Patent Examiner for medical devices and Humacyte conducting tissue engineering research. Megann received her M.B.A. from the Duke University Fuqua School of Business and her B.S.E. in Biomedical Engineering from Duke University Pratt School of Engineering. Megann is a mother of two young kids, wife, daughter, sister, reader, yogi and Peloton enthusiast.

As a Partner at Echo Health Ventures in Boston, Jessica A. Zeaske, PhD, MHS, MBA, identifies and invests in emerging and growth stage companies for Echo. She is a seasoned venture capitalist and board leader having worked at independent, corporate, and university funds and written dozens of investment themes over the years. She previously served as Director of Healthcare Investments at GE Ventures where she invested in precision health companies. Jessica came to GE Ventures from Lemhi Ventures, a fund investing in health care services with a focus on market disruption. Prior to joining Lemhi, Jessica worked on forming and spinning out MedTech and Life Science companies based on University intellectual property at U of Minnesota and Oregon Health & Science University. Jessica began her career writing software for a start-up health care delivery company. She then moved to a merchant bank, Greenspring Advisors, where they launched and invested in data-driven health care start-up companies. Jessica received an undergraduate degree with honors from Stanford University, graduated from Johns Hopkins School of Public Health with a Master of Health Science and PhD, and completed her MBA with a focus on Healthcare Administration at Regis University. Jessica currently serves on the Boards of Avalon Healthcare Services, Genome Medical and Wildflower Health and is a Board Observer at Abacus Insights. Her previous Board of Director experience includes Apervita, Arcadia.io, PlanSource, OneHealth, PokitDok, Orasi Medical, Medication Management Solutions, plus significant work at Bind On-Demand Health Insurance. Jessica also serves on the Board of DentaQuest Partnership for Oral Health Advancement, is a Trustee for Boston Medical Center's Exceptional Care Without Exception Trust, is an Advisory Board member for Boston Children's Hospital, and is a member of the National Association of Corporate Directors.